Tech Company Financing Transactions

Lux Biosciences Funding Round

HBM Healthcare Investments, Novo Ventures and Prospect Venture Partners invested in a $50 million Series B funding round for Lux Biosciences. The funding round was announced on 10/19/2009.

Transaction Overview

Company Information

Company Status

Out of Business

Industry

Biopharmaceutical

Mailing Address

3 Second Street 14th Floor
Jersey City, NJ 07302
USA

Phone

(201) 946-0551

Website

www.luxbio.com

Email Address

[email protected]

Overview

Lux Biosciences is a biotechnology company specialized in the field of ophthalmic diseases. We are developing medications to treat the underlying causes of these diseases and alleviate their symptoms. Ultimately, we strive to improve or preserve the eyesight of patients with these diseases.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Dean Mitchell

        

Chief Medical Officer

Eddy Anglade

        

Chief Operating Officer

Clarke Atwell

        

Browse more venture capital transactions:

Prev: 10/19/2009: ClearCount Medical Solutions venture capital transaction
Next: 10/20/2009: Currensee venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary